Potential role of histamine releasing factor (HRF) as a therapeutic target for treating asthma and allergy

Research output: Contribution to journalArticle

Abstract

Histamine releasing factor (HRF), also known as translationally controlled tumor protein (TCTP), is a highly conserved, ubiquitous protein that has both intracellular and extracellular functions. Here, we will highlight the history of the molecule, its clinical implications with a focus on its extracellular functioning, and its potential role as a therapeutic target in asthma and allergy. The cells and cytokines produced when stimulated or primed by HRF/TCTP are detailed as well as the downstream signaling pathway that HRF/TCTP elicits. While it was originally thought that HRF/TCTP interacted with IgE, the finding that cells not binding IgE also respond to HRF/TCTP called this interaction into question. HRF/TCTP, or at least its mouse counterpart, appears to interact with some, but not all IgE and IgG molecules. HRF/TCTP has been shown to activate multiple human cells including basophils, eosinophils, T cells, and B cells. Since many of the cells activated by HRF/TCTP participate in the allergic response, extracellular functions of HRF/TCTP may exacerbate the allergic, inflammatory cascade. Particularly exciting is that small molecule agonists of Src homology 2-containing inositol phosphatase-1 have been shown to modulate the phosphoinositide 3-kinase/AKT pathway and may control inflammatory disorders. This review discusses this possibility in light of HRF/TCTP.

Original languageEnglish (US)
Pages (from-to)51-59
Number of pages9
JournalJournal of Asthma and Allergy
Issue number5
DOIs
StatePublished - 2012

Fingerprint

Hypersensitivity
Asthma
Therapeutics
translationally-controlled 1 tumor protein
Immunoglobulin E
1-Phosphatidylinositol 4-Kinase
Basophils
Eosinophils

Keywords

  • Human basophils
  • Human eosinophils
  • Inducible transgenic mouse
  • Interleukin 13
  • Interleukin 4
  • Translationally controlled tumor protein (TCTP)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

@article{c4588ecb48ea4157b7eacddfdf83d770,
title = "Potential role of histamine releasing factor (HRF) as a therapeutic target for treating asthma and allergy",
abstract = "Histamine releasing factor (HRF), also known as translationally controlled tumor protein (TCTP), is a highly conserved, ubiquitous protein that has both intracellular and extracellular functions. Here, we will highlight the history of the molecule, its clinical implications with a focus on its extracellular functioning, and its potential role as a therapeutic target in asthma and allergy. The cells and cytokines produced when stimulated or primed by HRF/TCTP are detailed as well as the downstream signaling pathway that HRF/TCTP elicits. While it was originally thought that HRF/TCTP interacted with IgE, the finding that cells not binding IgE also respond to HRF/TCTP called this interaction into question. HRF/TCTP, or at least its mouse counterpart, appears to interact with some, but not all IgE and IgG molecules. HRF/TCTP has been shown to activate multiple human cells including basophils, eosinophils, T cells, and B cells. Since many of the cells activated by HRF/TCTP participate in the allergic response, extracellular functions of HRF/TCTP may exacerbate the allergic, inflammatory cascade. Particularly exciting is that small molecule agonists of Src homology 2-containing inositol phosphatase-1 have been shown to modulate the phosphoinositide 3-kinase/AKT pathway and may control inflammatory disorders. This review discusses this possibility in light of HRF/TCTP.",
keywords = "Human basophils, Human eosinophils, Inducible transgenic mouse, Interleukin 13, Interleukin 4, Translationally controlled tumor protein (TCTP)",
author = "MacDonald, {Susan M}",
year = "2012",
doi = "10.2147/JAA.S28868",
language = "English (US)",
pages = "51--59",
journal = "Journal of Asthma and Allergy",
issn = "1178-6965",
publisher = "Dove Medical Press Ltd.",
number = "5",

}

TY - JOUR

T1 - Potential role of histamine releasing factor (HRF) as a therapeutic target for treating asthma and allergy

AU - MacDonald, Susan M

PY - 2012

Y1 - 2012

N2 - Histamine releasing factor (HRF), also known as translationally controlled tumor protein (TCTP), is a highly conserved, ubiquitous protein that has both intracellular and extracellular functions. Here, we will highlight the history of the molecule, its clinical implications with a focus on its extracellular functioning, and its potential role as a therapeutic target in asthma and allergy. The cells and cytokines produced when stimulated or primed by HRF/TCTP are detailed as well as the downstream signaling pathway that HRF/TCTP elicits. While it was originally thought that HRF/TCTP interacted with IgE, the finding that cells not binding IgE also respond to HRF/TCTP called this interaction into question. HRF/TCTP, or at least its mouse counterpart, appears to interact with some, but not all IgE and IgG molecules. HRF/TCTP has been shown to activate multiple human cells including basophils, eosinophils, T cells, and B cells. Since many of the cells activated by HRF/TCTP participate in the allergic response, extracellular functions of HRF/TCTP may exacerbate the allergic, inflammatory cascade. Particularly exciting is that small molecule agonists of Src homology 2-containing inositol phosphatase-1 have been shown to modulate the phosphoinositide 3-kinase/AKT pathway and may control inflammatory disorders. This review discusses this possibility in light of HRF/TCTP.

AB - Histamine releasing factor (HRF), also known as translationally controlled tumor protein (TCTP), is a highly conserved, ubiquitous protein that has both intracellular and extracellular functions. Here, we will highlight the history of the molecule, its clinical implications with a focus on its extracellular functioning, and its potential role as a therapeutic target in asthma and allergy. The cells and cytokines produced when stimulated or primed by HRF/TCTP are detailed as well as the downstream signaling pathway that HRF/TCTP elicits. While it was originally thought that HRF/TCTP interacted with IgE, the finding that cells not binding IgE also respond to HRF/TCTP called this interaction into question. HRF/TCTP, or at least its mouse counterpart, appears to interact with some, but not all IgE and IgG molecules. HRF/TCTP has been shown to activate multiple human cells including basophils, eosinophils, T cells, and B cells. Since many of the cells activated by HRF/TCTP participate in the allergic response, extracellular functions of HRF/TCTP may exacerbate the allergic, inflammatory cascade. Particularly exciting is that small molecule agonists of Src homology 2-containing inositol phosphatase-1 have been shown to modulate the phosphoinositide 3-kinase/AKT pathway and may control inflammatory disorders. This review discusses this possibility in light of HRF/TCTP.

KW - Human basophils

KW - Human eosinophils

KW - Inducible transgenic mouse

KW - Interleukin 13

KW - Interleukin 4

KW - Translationally controlled tumor protein (TCTP)

UR - http://www.scopus.com/inward/record.url?scp=84874785758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874785758&partnerID=8YFLogxK

U2 - 10.2147/JAA.S28868

DO - 10.2147/JAA.S28868

M3 - Article

C2 - 23055753

AN - SCOPUS:84874785758

SP - 51

EP - 59

JO - Journal of Asthma and Allergy

JF - Journal of Asthma and Allergy

SN - 1178-6965

IS - 5

ER -